Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Our choice today is cinnamon hazelnut, for those tracking this sort of thing. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. …
Endo International became the latest pharmaceutical company to file for bankruptcy under the weight of lawsuits alleging it played a role in fueling the opioid crisis, The Wall Street Journal notes. The drugmaker filed for chapter 11 protection after struggling with more than $8 billion in debt, competition from generic manufacturers, and opioid litigation. Endo said that most of its first-lien creditors have agreed to buy the business out of bankruptcy, in return for $6 billion in debt forgiveness. Endo has faced thousands of lawsuits over the marketing and sale of its painkiller Opana ER, which the company discontinued in 2017 at the request of the U.S. Food and Drug Administration.
The plaintiff in the first lawsuit over the Zantac heartburn drug scheduled to go to trial has agreed to drop his case, Reuters writes. The first trial in one of those lawsuits had been scheduled to begin on Monday in an Illinois state court. The plaintiff, Joseph Bayer, alleged that he developed esophageal cancer from taking over-the-counter Zantac. Alexandra Walsh, an attorney for Bayer, said her client could not proceed for “personal health reasons” but had the right to refile his case within a year. Zantac, originally marketed by a forerunner of GSK, has been sold by several brand-name companies. Separately, a few generic drugmakers agreed to settle with Bayer for a total of more than $500,000.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
